Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.
暂无分享,去创建一个
Jan Lubinski | Alan Ashworth | Susan Shanley | John Stone | James Carmichael | Johann S de Bono | David S Boss | Charlie Gourley | Timothy A Yap | Christina Messiou | Roger A'Hern | A. Ashworth | A. Tutt | J. Lubiński | J. Carmichael | J. Schellens | S. Shanley | R. A’Hern | S. Kaye | T. Yap | D. Boss | C. Gourley | C. Messiou | J. D. de Bono | M. Mergui-Roelvink | J. De Grève | P. Fong | Jan H M Schellens | Andrew Tutt | Craig P Carden | Stan B Kaye | Peter C Fong | Marja Mergui-Roelvink | Jacques De Greve | C. Carden | J. Stone
[1] Jorge S. Reis-Filho,et al. Resistance to therapy caused by intragenic deletion in BRCA2 , 2008, Nature.
[2] A. Ashworth,et al. Hallmarks of 'BRCAness' in sporadic cancers , 2004, Nature Reviews Cancer.
[3] L. Tanoue. Cancer Statistics, 2009 , 2010 .
[4] Timothy A. Yap,et al. Beyond chemotherapy: targeted therapies in ovarian cancer , 2009, Nature Reviews Cancer.
[5] A. Ashworth,et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.
[6] D. Patt,et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] R. L. Baldwin,et al. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. , 2000, Cancer research.
[8] L. Saal,et al. Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair , 2008, Nature Genetics.
[9] S. Gayther,et al. The Contribution of BRCA1 and BRCA2 to Ovarian Cancer , 2009, Molecular oncology.
[10] Alan Ashworth,et al. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Jung-Sik Kim,et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors , 2009, EMBO molecular medicine.
[12] P. Pandolfi,et al. Essential Role for Nuclear PTEN in Maintaining Chromosomal Integrity , 2007, Cell.
[13] M Van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.
[14] A. Shenton,et al. Probability of BRCA1/2 mutation varies with ovarian histology: results from screening 442 ovarian cancer families , 2008, Clinical genetics.
[15] A. Jemal,et al. Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.
[16] E. Eisenhauer,et al. Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). , 2005, Journal of the National Cancer Institute.
[17] P. Devilee,et al. Genetic analysis of a breast–ovarian cancer family, with 7 cases of colorectal cancer linked to BRCA1, fails to support a role for BRCA1 in colorectal tumorigenesis , 2000, International journal of cancer.
[18] A. Tutt,et al. Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] F. Couch,et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers , 2008, Nature.
[20] R. Agarwal,et al. Ovarian cancer: strategies for overcoming resistance to chemotherapy , 2003, Nature Reviews Cancer.
[21] J. Herman,et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. , 2000, Journal of the National Cancer Institute.
[22] Alan Ashworth,et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.
[23] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[24] F. Couch,et al. Edinburgh Research Explorer Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma , 2022 .
[25] Alan Ashworth,et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. , 2006, Cancer research.
[26] F. Collins,et al. Somatic mutations in the BRCA1 gene in sporadic ovarian tumours , 1995, Nature Genetics.
[27] Thomas Helleday,et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2007, Nature.
[28] P. Spellman,et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities , 2008, BMC Cancer.